AML cells in the G1 phase of the cell cycle were inhibited by HHT.[86] By blocking the MAPK/ERK and PI3K/AKT pathways and activating the p53 pathway, HHT improved the proapoptotic effects of venetoclax (Fig. 4). The gene discussed is MAPK1; the disease is acute myeloid leukemia.